ES2317245T3 - Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. - Google Patents

Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. Download PDF

Info

Publication number
ES2317245T3
ES2317245T3 ES05748688T ES05748688T ES2317245T3 ES 2317245 T3 ES2317245 T3 ES 2317245T3 ES 05748688 T ES05748688 T ES 05748688T ES 05748688 T ES05748688 T ES 05748688T ES 2317245 T3 ES2317245 T3 ES 2317245T3
Authority
ES
Spain
Prior art keywords
agonist
antagonist
combination
concurrent
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05748688T
Other languages
English (en)
Spanish (es)
Inventor
Jordi Gras Escardo
Jesus Llenas Calvo
Hamish Ryder
Pio Orviz Diaz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Laboratorios Almirall SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200401312A external-priority patent/ES2257152B1/es
Application filed by Laboratorios Almirall SA filed Critical Laboratorios Almirall SA
Application granted granted Critical
Publication of ES2317245T3 publication Critical patent/ES2317245T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES05748688T 2004-05-31 2005-05-31 Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. Expired - Lifetime ES2317245T3 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
ES200401312A ES2257152B1 (es) 2004-05-31 2004-05-31 Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
ES200401312 2004-05-31
EP2005001969 2005-02-24
WOEP2005/000196 2005-02-24
WOGB2005/000072 2005-02-25
WOGB2005/000074 2005-02-25
GB2005000740 2005-02-25
GB2005000722 2005-02-25

Publications (1)

Publication Number Publication Date
ES2317245T3 true ES2317245T3 (es) 2009-04-16

Family

ID=34968792

Family Applications (2)

Application Number Title Priority Date Filing Date
ES05748688T Expired - Lifetime ES2317245T3 (es) 2004-05-31 2005-05-31 Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
ES07023760T Expired - Lifetime ES2336144T3 (es) 2004-05-31 2005-05-31 Combinaciones que comprenden agentes antimuscarinicos y corticosteroides.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES07023760T Expired - Lifetime ES2336144T3 (es) 2004-05-31 2005-05-31 Combinaciones que comprenden agentes antimuscarinicos y corticosteroides.

Country Status (21)

Country Link
US (2) US20110224177A1 (Direct)
EP (5) EP1905451B1 (Direct)
JP (1) JP2012211183A (Direct)
AT (3) ATE419011T1 (Direct)
AU (3) AU2005247105B2 (Direct)
BE (1) BE2015C012I2 (Direct)
CA (3) CA2569074C (Direct)
CY (1) CY1110829T1 (Direct)
DE (3) DE602005012102D1 (Direct)
DK (2) DK1905451T3 (Direct)
ES (2) ES2317245T3 (Direct)
HR (3) HRP20090106T3 (Direct)
IL (3) IL179690A (Direct)
MX (3) MXPA06013846A (Direct)
NZ (3) NZ551669A (Direct)
PL (2) PL1891974T3 (Direct)
PT (3) PT1891974E (Direct)
RS (3) RS51422B (Direct)
RU (3) RU2379033C2 (Direct)
SI (3) SI1765404T1 (Direct)
WO (3) WO2005115463A1 (Direct)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP1859804B1 (en) * 2005-02-10 2016-12-07 Oncolys BioPharma, Inc. Anticancer agent combination therapy
KR20090121338A (ko) * 2007-02-19 2009-11-25 씨아이피엘에이 엘티디. 두 개 이상의 기관지확장제 또는 기관지확장제와 코르티코스테로이드의 약제학적 조합
EP2080523A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprising an antimuscarinic and a long-acting beta-agonist
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
GB0811100D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination
GB0814728D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
EP4403231A3 (en) 2009-02-26 2024-10-23 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
WO2010097114A1 (en) * 2009-02-26 2010-09-02 Glaxo Group Limited Novel combination of therapeutic agents
CN107501290A (zh) 2009-05-14 2017-12-22 天津合美医药科技有限公司 噻吩衍生物
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
BR112014025518B1 (pt) 2012-04-13 2022-05-24 Glaxosmithkline Intellectual Property Development Limited Partículas agregadas de umeclidinium, vilanterol e fluticasona, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de estearato de magnésio em partículas agregadas
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
CA2902400C (en) * 2013-03-15 2021-05-04 Verona Pharma Plc Pde3/4 inhibitor/.beta.2-adrenergic agonist combination
GB201308933D0 (en) * 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
MX382210B (es) * 2013-07-05 2025-03-13 Bioneer Corp (arnip) gen especifico relacionado con las enfermedades respiratorias, (arnip) que contiene la estructura arn oligo helicoidal, composicion que contiene la misma para prevencion o tratamiento de las enfermedades respiratorias.
TW201542207A (zh) * 2013-10-03 2015-11-16 Otsuka Pharma Co Ltd 嚴重氣喘治療劑

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
WO1992004928A2 (en) 1990-09-26 1992-04-02 Pharbita B.V. Inhaler devices provided with a reservoir for several doses of medium for inhaling, transporting device, whirl chamber
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
KR0163472B1 (ko) 1992-12-18 1998-11-16 에릭 에스. 딕커 분말 약품용 흡입기
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
KR100403899B1 (ko) 1995-04-14 2004-03-20 글락소 웰컴 인크. 살메테롤용정량흡입기
CA2378713C (en) 1995-06-21 2003-08-12 Asta Medica Aktiengesellschaft Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
DE19528145A1 (de) * 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009605D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
US7217409B2 (en) * 2000-09-22 2007-05-15 Smithkline Beecham Corporation Alkanoic acid derivatives
DE10062712A1 (de) 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
CA2733294C (en) 2000-10-31 2011-12-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical combination of a tiotropium salt and ciclesonide
DE10056104A1 (de) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
BR0116624A (pt) * 2000-12-28 2003-12-23 Almirall Prodesfarma Ag Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto ou da composição farmacêutica, e, produto de combinação
JP2004530705A (ja) * 2001-05-25 2004-10-07 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 閉塞性気道疾患及びその他の炎症性疾患を治療するためのｐｄｅ４インヒビター及びチオトロピウム又はその誘導体の組み合わせ
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
ES2206021B1 (es) * 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
MXPA04011383A (es) * 2002-05-17 2005-02-14 Novartis Ag Composicion farmaceutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diuretico.
CN101700247A (zh) * 2002-06-12 2010-05-05 埃匹吉尼斯医药有限公司 利用脱氢表雄酮甾体及抗毒蕈碱药物治疗呼吸道疾病及肺病的组合物、制剂和试剂盒
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
PT1610787E (pt) * 2003-03-28 2008-04-23 Nycomed Gmbh Associação sinérgica compreendendo roflumilast e um agente anticolinérgico seleccionado de sais de tiotrópio para o tratamento de doenças respiratórias
EP1610788A1 (en) * 2003-03-28 2006-01-04 ALTANA Pharma AG Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.

Also Published As

Publication number Publication date
US20110224177A1 (en) 2011-09-15
AU2005247106B2 (en) 2010-11-11
AU2005247104B2 (en) 2010-11-11
HK1096605A1 (en) 2007-06-08
SI1765404T1 (sl) 2009-04-30
ATE454904T1 (de) 2010-01-15
RU2006146673A (ru) 2008-07-20
IL179690A (en) 2012-10-31
WO2005115463A1 (en) 2005-12-08
EP1905451B1 (en) 2010-01-13
SI1905451T1 (sl) 2010-05-31
HRP20090106T3 (en) 2009-03-31
WO2005115465A1 (en) 2005-12-08
RS50786B (sr) 2010-08-31
EP1891974B1 (en) 2010-07-21
RS51206B (sr) 2010-12-31
CA2569074C (en) 2012-12-18
EP1891974A1 (en) 2008-02-27
AU2005247105B2 (en) 2010-11-11
NZ551669A (en) 2010-07-30
AU2005247104A1 (en) 2005-12-08
PT1765404E (pt) 2009-03-31
NZ551670A (en) 2010-07-30
RU2404772C2 (ru) 2010-11-27
BE2015C012I2 (Direct) 2024-10-08
AU2005247105A1 (en) 2005-12-08
CA2568568A1 (en) 2005-12-08
RU2006147269A (ru) 2008-07-20
EP2210614A1 (en) 2010-07-28
HRP20100490T1 (hr) 2010-10-31
US20130196961A1 (en) 2013-08-01
IL179685A (en) 2012-01-31
SI1891974T1 (sl) 2010-11-30
JP2012211183A (ja) 2012-11-01
PT1905451E (pt) 2010-03-31
DK1905451T3 (da) 2010-05-10
EP1905451A1 (en) 2008-04-02
ATE419011T1 (de) 2009-01-15
PL1905451T3 (pl) 2010-05-31
EP1765405A1 (en) 2007-03-28
DK1891974T3 (da) 2010-11-08
EP1761279A1 (en) 2007-03-14
MXPA06013850A (es) 2007-03-02
RU2379033C2 (ru) 2010-01-20
ATE474601T1 (de) 2010-08-15
RS51422B (sr) 2011-02-28
MXPA06013849A (es) 2007-03-01
HRP20100104T1 (hr) 2010-04-30
CA2568568C (en) 2012-12-18
RU2006146813A (ru) 2008-07-20
RU2385156C2 (ru) 2010-03-27
NZ551666A (en) 2010-07-30
AU2005247106A1 (en) 2005-12-08
DE602005018969D1 (de) 2010-03-04
CY1110829T1 (el) 2015-06-10
IL179690A0 (en) 2007-05-15
IL179685A0 (en) 2007-05-15
CA2569074A1 (en) 2005-12-08
CA2568571C (en) 2012-12-18
CA2568571A1 (en) 2005-12-08
DE602005022499D1 (de) 2010-09-02
IL179686A0 (en) 2007-05-15
MXPA06013846A (es) 2007-03-01
PT1891974E (pt) 2010-09-27
WO2005115464A1 (en) 2005-12-08
PL1891974T3 (pl) 2010-12-31
ES2336144T3 (es) 2010-04-08
DE602005012102D1 (de) 2009-02-12

Similar Documents

Publication Publication Date Title
ES2322280T3 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
ES2317245T3 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
HK1198120B (en) Combinations comprising antimuscarininc agents and beta-adrenergic agonists
HK1096605B (en) Combinations comprising antimuscarinic agents and beta-adrenergic agonists
HK1125573B (en) Combinations comprising antimuscarininc agents and beta-adrenergic agonists